CAS
NBIX icon

Coppell Advisory Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Coppell Advisory Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-190
Closed -$26K – 1299
2024
Q4 		$26K Sell
190
-247
-57% -$30.6K ﹤0.01% 777
2024
Q3 		$50.3K Buy
437
+247
+130% +$33.9K 0.01% 550
2024
Q2 		$26.2K Buy
+190
New +$26.1K ﹤0.01% 683
2023
Q4 		$27.1K Sell
206
-217
-51% -$25K 0.01% 647
2023
Q3 		$50.5K Buy
+423
New +$44.5K 0.02% 295
2023
Q1 		– Sell
-423
Closed -$50.5K – 752
2022
Q4 		$50.5K Buy
+423
New +$49.5K 0.02% 296

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Coppell Advisory Solutions's NBIX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 190 shares — an estimated $26K sold.

Coppell Advisory Solutions first reported a position in NBIX in Q4 2022 and held it in 6 quarters. The position peaked at $50.5K in Q3 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 190 Neurocrine Biosciences shares in Q1 2025, an estimated $26K.
  • Coppell Advisory Solutions first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 6 quarters.
  • Coppell Advisory Solutions's Neurocrine Biosciences position peaked at $50.5K in Q3 2023.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.